Ajay K. Gopal

Research interests

Publications

• Diagnosis and Management of Multiple Myeloma

  JAMA · 2022 · https://doi.org/10.1001/jama.2022.0003

• Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.02103

• Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01994

• Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-17-1922

• International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx097

• Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

  Blood · 2016 · 10.1182/blood-2016-02-699850

• Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

  Journal of Hematology & Oncology · 2014 · 10.1186/1756-8722-7-24

• Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

  Blood · 2014 · 10.1182/blood-2014-08-595801

• Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

  Blood · 2014 · 10.1182/blood-2014-08-595801

• Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

  Journal of Hematology & Oncology · 2014 · 10.1186/1756-8722-7-24

• PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1314583

• Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131 Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2012.42.4101

• Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.38.0410

• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

  Blood · 2012 · https://doi.org/10.1182/blood-2011-10-387969

• Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131 Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2012.42.4101

• Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.31.8121

• Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

  Blood · 2009 · 10.1182/blood-2009-03-213298

• Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

  Blood · 2009 · 10.1182/blood-2009-03-213298

• A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

  British Journal of Haematology · 2009 · 10.1111/j.1365-2141.2009.07740.x

• Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

  Blood · 2008 · https://doi.org/10.1182/blood-2007-12-128843

• High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis

  Blood · 2003 · 10.1182/blood-2003-02-0622

• High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis

  Blood · 2003 · 10.1182/blood-2003-02-0622

• High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

  Blood · 2002 · 10.1182/blood.v99.9.3158

• High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

  Blood · 2002 · 10.1182/blood.v99.9.3158

• A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

  Blood · 2000 · 10.1182/blood.v96.9.2934

• A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

  Blood · 2000 · 10.1182/blood.v96.9.2934.h8002934_2934_2942

• Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients

  Kidney International · 1998 · https://doi.org/10.1046/j.1523-1755.1998.00134.x

• Outcome of Staphylococcus aureus Bacteremia According to Compliance with Recommendations of Infectious Diseases Specialists: Experience with 244 Patients

  Clinical Infectious Diseases · 1998 · 10.1086/514686

• Role of Echocardiography in Evaluation of Patients With Staphylococcus aureusBacteremia: Experience in 103 Patients

  Journal of the American College of Cardiology · 1997 · 10.1016/s0735-1097(97)00250-7

Current projects

No projects listed.